Hematology

Research advances personalized cancer therapy.

Catch up with the latest developments in cancer research.

Weight cycling may influence the biological processes that can lead to cancer.

High cost of research and development causes less investment by pharmaceutical firms.

Study finds significant barriers to health care access, including stigmatization.

Novel oral soluble film is indicated to prevent highly and moderately emetogenic chemotherapy-induced nausea and vomiting.

Particles are surrounded by a protective coating to release drugs in the presence of a specific tumor enzyme.

Kyprolis treats patients who received at least 2 prior therapies and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Silver is a useful element to prevent bacterial growth.

Study finds less than half of cancer patients have a completed will.

Five pivotal phase 3 trial ongoing for oral proteasome inhibitor.

Discovery may lead to cost effective treatment options.

Access is open to US adult patients who are refractory to the most common anti-myeloma drug classes.

Multiple myeloma patients in immediate need of new treatment options can receive Janssen's investigational daratumumab through an expanded access program (EAP).

Patients face significant financial burdens from treatment.

Combination of immunotherapy and epigenetics put patients into remission, even after failing the standard treatment.

Size and speed of tumor growth similar in dogs and humans.

Increasing immune cell infiltration into tumors induces the immune system to block tumor growth.

Lipid from avocados targets leukemia stem cells.

Early palliative care reduces costs more than traditional treatment standards.

Promacta is the first and only oral thrombopoietin-receptor agonist that increases platelet production.

Drug is being evaluated for the treatment of patients who received at least 3 prior lines of therapy.

Glioblastoma treatment with surgical resection may benefit patients with worst prognoses.

Undertreated side effects in treatment of some colon and stomach cancers need to be addressed.

Janssen has submitted a Biologic License Application to the FDA seeking daratumumab's approval in multiple myeloma.